VC-backed Sienna Biopharmaceuticals goes public
Westlake Village, California and Italy-based Sienna Biopharmaceuticals Inc, a clinical stage medical dermatology and aesthetics company, has debuted its IPO after pricing its over 4.3 million shares at $15 per share. The stock began trading Thursday July 27 on the NASDAQ under the ticker symbol “SNNA." J.P. Morgan and Cowen are serving as the lead underwriters. Sienna Biopharmaceutical's pre-IPO backers include ARCH Venture Partners, Venvest Capital, Partner Fund Management, Altitude Life Science Ventures and Fidelity Management & Research Company.
27 July 2017•3 mins read
